# The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy

> **NCT00115895** · PHASE3 · UNKNOWN · sponsor: **University of Helsinki** · enrollment: 160 (actual)

## Conditions studied

- Thyroid Neoplasms

## Interventions

- **DRUG:** Radioactive iodine

## Key facts

- **NCT ID:** NCT00115895
- **Lead sponsor:** University of Helsinki
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2000-01
- **Primary completion:** 2004-10
- **Final completion:** 2020-09
- **Target enrollment:** 160 (ACTUAL)
- **Last updated:** 2018-03-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00115895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00115895, "The Dose of Radioactive Iodine Needed to Ablate the Thyroid Remnant Left Behind After Thyroidectomy". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT00115895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*